Revival Health has entered into a strategic partnership with Quanta Computer to scale-up manufacturing capabilities of Covid-19 and blood biomarker tests.

According to a company statement, Revival seeks to achieve a domestic Covid-19 Rapid Tests manufacturing capacity of 15 to 20 million units a month in the US.

The collaboration will enable Revival to leverage Quanta’s manufacturing and robotics operational expertise for its rapid testing platform, LumiNow, and healthcare ecosystem, Move 78.

LumiNow enables lab-free, 20-minute antigen testing for SARS-CoV-2, the virus which causes Covid-19.

The LumiNow digital lateral flow test (LFT) features spectral sensing capabilities, enables quantitative verification and offers results through Bluetooth to a smartphone app. The data is processed in a secure medical Cloud.

Revival vice-president Brandon Wu said: “Our goal is to be largest and most automated manufacturer of lateral flows assays in the US. Our partnership with Quanta makes that a reality.”

Headquartered in Taiwan, Quanta Computer focuses on producing notebook computers, datacentre equipment and technology products.

The Taiwanese company has major operation facilities in Asia, North America, South America and Europe. Currently, it employs approximately 90,000 people globally.

Commenting on the partnership with Revival, Quanta Computer vice-president Frank Chuang said: “Quanta is excited to bring our best-in-class manufacturing capabilities to this partnership with Revival Health, to help increase Covid-19 testing supply and contribute towards mitigating the impact of this pandemic.”

Revival Health was founded to address preventative care issues. It offers an ecosystem of hardware, software and services to facilitate the diagnosis and treatment of diseases.